Trovagene announces completion of second dosing of patients treated with Onvansertib
Trovagene announced completion of the second dosing cohort of Onvansertib, a first-in-class, 3rd generation, highly-selective oral Polo-like Kinase 1 Inhibitor, in combination with standard-of-care low-dose cytarabine, in its Phase 1b/2 clinical trial in patients with Acute Myeloid Leukemia. August 16, 2018